Prolactin Level in Polycystic Ovary Syndrome (PCOS): An approach to the diagnosis and management

Zahra Davoudi; Farnaz Araghi; Maryam Vahedi; Navid  Mokhtari; Mehdi Gheisari

doi:10.23750/abm.v92i5.9866

Prolactin Level in Polycystic Ovary Syndrome (PCOS): An approach to the diagnosis and management

Authors

Zahra Davoudi
Farnaz Araghi
Maryam Vahedi
Navid Mokhtari
Mehdi Gheisari a:1:{s:5:"en_US";s:46:"Shahid Beheshti University of Medical Sciences";}

DOI: https://doi.org/10.23750/abm.v92i5.9866

Keywords:

Hyperprolactinemia, Polycystic ovary syndrome, Macroprolactin, Menstrual dysfunction

Abstract

Introduction: In spite of the increasing prevalence of polycystic ovary syndrome, there are restricted studies about different features of PCOS. In this study, we evaluate serum prolactin levels in PCOS patients and compare clinical features and hormone levels between patients with hyperprolactinemia and normal levels of prolactin. Methods: Serum prolactin level in 330 PCOS patients were evaluated. If the prolactin levels were normal (equal to or less than 25 ng/ml) the patient was considered normal. If the prolactin levels were >25 ng/ml, then the level was measured by Polyethylene glycol (PEG) precipitation method to detect macroprolactinemia. Furthermore, brain MRI was done in case of hyperprolactinemia to discover pituitary adenoma. Results: Among 330 patients with PCOS, 208 (63.4%) had normal prolactin levels and 122 (37%) patients had hyperprolactinemia. Among hyperprolactinemic patients, 72 (59%) had normal prolactin levels after PEG precipitation and 33 (27%) patients had pituitary adenoma in their brain MRI and 17 (13%) patients were considered as idiopathic hyperprolactinemia with normal MRI. Further, higher levels of LH and LH/FSH ratio and lower estradiol levels were observed in patients with normal prolactin levels. Also, menstrual disorders were more prevalent among patients with pituitary adenoma. Conclusions: Investigating increased level of prolactin in PCOS patients is recommended to detect the causes of hyperprolactinemia, especially macroprolactinemia.

References

1. Bani Mohammad M, Majdi Seghinsara A. Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH. Asian Pac J Cancer Prev. 2017;18(1):17-21.
2. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HcF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. The Journal of Clinical Endocrinology & Metabolism. 2000;85(7):2434-8.
3. Lujan ME, Chizen DR, Pierson RA. Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. Journal of obstetrics and gynaecology Canada. 2008;30(8):671-9.
4. Melgar V, Espinosa E, Sosa E, Rangel MJ, Cuenca D, Ramírez C, et al. Current diagnosis and treatment of hyperprolactinemia. Revista Médica del Instituto Mexicano del Seguro Social. 2016;54(1):110-21.
5. Webster J. Dopamine agonist therapy in hyperprolactinemia. The Journal of reproductive medicine. 1999;44(12 Suppl):1105-10.
6. Soto-Pedre E, Newey PJ, Bevan JS, Greig N, Leese GP. The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS). Clin Endocrinol (Oxf). 2017;86(1):60-7.
7. Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. Cmaj. 2003;169(6):575-81.
8. Vilar L, Fleseriu M, Bronstein MD. Challenges and pitfalls in the diagnosis of hyperprolactinemia. Arquivos Brasileiros de Endocrinologia & Metabologia. 2014;58(1):9-22.
9. Vilar L, Abucham J, Albuquerque JL, Araujo LA, Azevedo MF, Boguszewski CL, et al. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2018;62(2):236-63.
10. Shimatsu A, Hattori N. Macroprolactinemia: diagnostic, clinical, and pathogenic significance. Clin Dev Immunol. 2012;2012:167132.
11. Hattori N, Inagaki C. Anti-prolactin (PRL) autoantibodies cause asymptomatic hyperprolactinemia: bioassay and clearance studies of PRL-immunoglobulin G complex. J Clin Endocrinol Metab. 1997;82(9):3107-10.
12. Olukoga AO, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxf). 1999;51(1):119-26.
13. Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab. 2002;87(2):581-8.
14. Suliman AM, Smith TP, Gibney J, McKenna TJ. Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. Clin Chem. 2003;49(9):1504-9.
15. Karasek M, Pawlikowski M, Lewiński A. Hyperprolactinemia: causes, diagnosis, and treatment. Endokrynologia Polska. 2006;57(6):656-62.
16. Zawadzki J, Dunaif A. Diagnostic criteria for polycystic syndrome: towards a rational approach. Dunaif A, Givens JR, Haseltine FP, and others, Eds Polycystic ovary syndrome Boston: Blackwell Scientific. 1992:337-84.
17. Szosland K, Pawlowicz P, Lewinski A. Prolactin secretion in polycystic ovary syndrome (PCOS). Neuroendocrinology Letters. 2015;36(1).
18. Robin G, Catteau-Jonard S, Young J, Dewailly D. Physiopathological link between polycystic ovary syndrome and hyperprolactinemia: myth or reality? Gynecologie, obstetrique & fertilite. 2011;39(3):141-5.
19. Tzingounis V, Alperin H, Natrajan P. Radiographic abnormalities in patients with Stein-Leventhal syndrome. Int J Gynaecol Obstet. 1978;16(2):167-9.
20. Franks S. Polycystic ovary syndrome. New England Journal of Medicine. 1995;333(13):853-61.
21. Filho RB, Domingues L, Naves L, Ferraz E, Alves A, Casulari LA. Polycystic ovary syndrome and hyperprolactinemia are distinct entities. Gynecological endocrinology. 2007;23(5):267-72.
22. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocrine reviews. 2015;36(5):487-525.
23. Sherazi NA, Baig MZ, Khan AH. Frequency of Macroprolactin in Hyperprolactinemia. J Coll Physicians Surg Pak. 2018;28(2):93-7.
24. Lu C-C, Hsieh C-J. The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients. The Kaohsiung journal of medical sciences. 2012;28(2):94-9.
25. Yen S, Ehara Y, Siler T. Augmentation of prolactin secretion by estrogen in hypogonadal women. The Journal of clinical investigation. 1974;53(2):652-5.
26. Carmina E, Rosato F, Maggiore M, Gagliano AM, Indovina D, Jannì A. Prolactin secretion in polycystic ovary syndrome (PCO): correlation with the steroid pattern. European Journal of Endocrinology. 1984;105(1):99-104.
27. Shao S, Li X. Clinical features and analysis in 1385 Chinese patients with pituitary adenomas. J Neurosurg Sci. 2013;57(3):267-75.
28. Kulshreshtha B, Pahuja I, Kothari D, Chawla I, Sharma N, Gupta S, et al. Menstrual Cycle Abnormalities in Patients with Prolactinoma and Drug-induced Hyperprolactinemia. Indian J Endocrinol Metab. 2017;21(4):545-50.
29. Bahceci M, Tuzcu A, Bahceci S, Tuzcu S. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? Journal of endocrinological investigation. 2003;26(7):655-9.